BOSTON & LYON, Frankrijk–(BUSINESS WIRE)– ERYTECH, het Franse biofarmaceutische bedrijf dat innovatieve behandelingen van acute leukemie en andere kankersoorten door middel van ‘uithongering’ van tumoren ontwikkelt, benoemt Iman El-Hariry tot medisch bestuurder. El-Hariry is uit hoofde van die functie verantwoordelijk voor internationale medische, klinische en regelgeving betreffende zaken.
El-Hariry is een oncoloog met meer dan vijftien jaar ervaring in internationale productontwikkeling in de wereldwijde biofarmaceutische industrie, onder meer in de gedaante van vicevoorzitter klinisch onderzoek bij Syntha Pharmaceuticals, internationaal hoofd oncologie van Astellas APGD (in Chicago) en groepshoofd klinische oncologie van GSK (Londen). Ze leidde met succes de ontwikkeling en officiële goedkeuringen van verscheidene producten in Europa en de Verenigde Staten. Als medisch directeur van ERYTECH zal Iman vanuit Boston werkzaam zijn.
ERYTECH Appoints Dr. Iman El-Hariry as Chief Medical Officer
BOSTON & LYON, France–(BUSINESS WIRE)– Regulatory News:
ERYTECH Inc., the US affiliate of ERYTECH Pharma (Euronext Paris: ERYP) (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs.
Iman El-Hariry, M.D., Ph.D., is an oncologist with more than 15 years of global product development experience in the global biopharmaceutical industry, including as VP Clinical Research with Syntha Pharmaceuticals (Boston), Global Head Oncology at Astellas APGD (Chicago) and Group Director Clinical Oncology at GSK (London). She has successfully led the development and regulatory approvals of different products both in Europe and in the United States. As Chief Medical Officer at ERYTECH Inc., based in Boston, Iman will be responsible for global medical, clinical and regulatory affairs. Her key priorities will be the registration of ERYASP/GRASPA® in Europe in Acute Lymphoblastic Leukemia, the supervision of the ongoing clinical studies in AML and Pancreas cancer in Europe, and the development of ERYASP in the United States. She has already been advising the company on a consulting basis over the past months.
Dr. El-Hariry holds an M.D. (Hons) from Alexandria Medical School, Alexandria, Egypt and a Ph.D. from the Imperial College of Science and Medicine, London, UK.
“This is a tremendously exciting time to be joining ERYTECH” said Dr. El-Hariry. “Enzyme entrapment into red blood cells is an innovative platform that provides a huge potential to be a major breakthrough for cancer patients. GRASPA® is the lead compound, with compelling activity, and favorable safety profile in patients with relapsed acute lymphoblastic leukemia. ERYMET is another exciting novel program, which represents a truly novel approach to treating cancer. I look forward to working on these programs”.
“We are very pleased to welcome Iman on board. Iman brings a wealth of experience in the relevant dimensions of oncology development and regulatory affairs both in Europe and the US, and will be key in realizing our ambitious plans.” comments Gil Beyen, Chairman & CEO of ERYTECH Pharma.
About ERYTECH and ERY-ASP/GRASPA®: www.erytech.com
Founded in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors. By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA®, an original treatment that targets cancer cells through “tumor starvation” while significantly reducing the side effects for patients. ERY-ASP/GRASPA® has recently announced positive Phase III data in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product is also in Phase I clinical development in ALL in the USA.
Every year about 50,000 patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute leukemia. Today, for about 80% of these patients, mainly adults and relapsing patients, current forms of asparaginase cannot be used due to their toxicity. With a presumed improved safety profile, ERY-ASP/GRASPA® is being developed to allow all leukemia patients to be treated, even the most fragile ones, representing a market opportunity of more than EUR 1 billion.
The company is also developing other indications in solid tumors and certain orphan indications outside oncology. A Phase II study in pancreas cancer is ongoing and the company is exploring other solid tumor indications for ERY-ASP.
ERYTECH has obtained orphan drug designations for ERY-ASP/GRASPA® in ALL, AML and pancreas cancer, both in Europe and the USA, and has its own GMP-approved and operational manufacturing site in Lyon (France), and a site for clinical production in Philadelphia (USA). The company has concluded licensing and distribution partnership agreements for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL with TEVA in Israel.
ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the US under an ADR level 1 program (OTC, ticker EYRYY).
This document may contain forward-looking statements and estimates with respect to the financial situation, the results of operations, the strategy, the project and to the anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company’s control. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results, the financial condition, performance or achievements of ERYTECH, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (
www.amf-france.org), also available on our website (
www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. ERYTECH disclaims any obligation to update any such forward-looking statement. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by French law.
Chairman and CEO
+33 4 78 74 44 38
Perez / Emmanuel Huynh
Tel: +33 1 44 71 98 52